P
Philipp Oster
Researcher at Sanofi Pasteur
Publications - 56
Citations - 3125
Philipp Oster is an academic researcher from Sanofi Pasteur. The author has contributed to research in topics: Meningococcal vaccine & MeNZB. The author has an hindex of 31, co-authored 51 publications receiving 2964 citations. Previous affiliations of Philipp Oster include Norwegian Institute of Public Health & Novartis.
Papers
More filters
Journal ArticleDOI
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Johan Holst,Diana L. Martin,Richard Arnold,Concepcion Campa Huergo,Philipp Oster,Jane O'Hallahan,Einar Rosenqvist +6 more
TL;DR: There is good reason to believe that in the coming few years the "OMV-concept" will be exploited further and that a number of cross-protective "universal" antigens will be included in vaccines against serogroup B meningococcal disease.
Journal ArticleDOI
MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.
TL;DR: It is suggested that MeNZB is safe and is likely to confer protection against systemic group B meningococcal disease caused by the epidemic strain.
Journal ArticleDOI
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
Jamie Findlow,Ray Borrow,Matthew D. Snape,Tom A. Dawson,Ann Holland,Tessa M. John,Anita Evans,Karen L. Telford,Ellen Ypma,Daniela Toneatto,Philipp Oster,Elizabeth Miller,Andrew J. Pollard +12 more
TL;DR: The rMenB+OMV vaccine has the potential to protect infants from MenB disease, although the breadth of protection afforded to heterologous antigens requires additional investigation.
Journal ArticleDOI
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
Matthew D. Snape,Tom A. Dawson,Philipp Oster,Anita Evans,Tessa M. John,Brigitte Ohene-Kena,Jamie Findlow,Ly-Mee Yu,Ray Borrow,Ellen Ypma,Daniela Toneatto,Andrew J. Pollard +11 more
TL;DR: Three doses of rMenB+OMV in the second half of infancy induce bactericidal antibodies against strains expressing vaccine antigens, demonstrating the potential for broader vaccine prevention of MenB disease.
Journal ArticleDOI
Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future
Johan Holst,Philipp Oster,Richard Arnold,Michael V. Tatley,Lisbeth Meyer Næss,Ingeborg S. Aaberge,Yvonne Galloway,Anne McNicholas,Jane O'Hallahan,Einar Rosenqvist,Steven Black +10 more
TL;DR: The public health intervention in New Zealand (between 2004–2008) when MeNZB was used to control a clonal MenB epidemic provided a number of new insights regarding international and public-private collaboration, vaccine safety surveillance, vaccine effectiveness estimates and communication to the public.